Document is current
Any future updates will be listed below
-
Authors
Fan, Xiaoyu
Ważyńska, Marta A.
Kol, Arjan
Perujo Holland, Noemi
Fernandes, Bruna
van Duijnhoven, Sander M. J.
Plat, Annechien
van Eenennaam, Hans
Elsinga, Philip H.
Nijman, Hans W.
de Bruyn, Marco http://orcid.org/0000-0001-9819-9131
-
Funding
Funding for this research was provided by:
Health~Holland (LSHM18073)
China Sponsorship Council (201906210060)
- License Information
-
More Information
Article History
Received: 11 May 2023
Accepted: 16 October 2023
First Online: 20 November 2023
Declarations
:
: Animal experiments were planned and performed under approval of the Institutional Animal Care and Use Committee of the University of Groningen in agreement with EU Directive 2010/63/EU (IvD: 16395-01-019). The study was also carried out in compliance with the ARRIVE guideline.
: Not applicable.
: A. Kol, S. van Duijnhoven, H. van Eenennaam, H.W. Nijman and M. de Bruyn are co-inventors on a patent owned by Aduro Biotech and University Medical Center Groningen that describes antibodies targeting CD103 (patent no. 62/704258).
